### Guideline Page and Request

**NSCL-17/26, NSCL-I**  
Panel request to review the data for larotrectinib as a treatment option for NTRK gene fusion positive metastatic NSCLC.

External request: Submission from Bayer Healthcare, requesting review of the data supporting the inclusion of larotrectinib for the treatment of patients with NTRK fusion positive metastatic NSCLC. The request also included updates to the Principles of Molecular and Biomarker Analysis section (NSCL-G).

### Panel Discussion/References

Based upon review of the data in the noted references, the panel consensus supported the addition of larotrectinib as a first-line/subsequent treatment option for NTRK gene fusion positive metastatic NSCLC. The following footnote was added to the testing section for advanced or metastatic disease (NSCL-17): Testing should include the neurotrophic receptor tyrosine kinase (NTRK) gene fusion; if positive, see NSCL-26. A new page was added to address the treatment recommendations for NTRK gene fusion positive metastatic NSCLC (NSCL-26). The panel consensus supported a category 2A recommendation.

The panel has deferred discussion of the recommended additions to the Principles of Molecular and Biomarker Analysis (NSCL-G) to the annual meeting.

- See Submission for references.

<table>
<thead>
<tr>
<th>YES</th>
<th>NO</th>
<th>ABSTAIN</th>
<th>ABSENT</th>
</tr>
</thead>
<tbody>
<tr>
<td>22</td>
<td>0</td>
<td>1</td>
<td>5</td>
</tr>
</tbody>
</table>